- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Placebo, CDK4/6i, Letrozole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 61
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 35 Years to 120 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- alpelisib, buparlisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Los Angeles, California + 16 more
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Burbank, California • Corona, California + 17 more
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Exemestane, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 63
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1455
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
- Conditions
- Breast Cancer
- Interventions
- ZARNESTRA, tipifarnib, R115777
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 6
- States / cities
- Miami, Florida • Chicago, Illinois • Durham, North Carolina + 3 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Ribociclib, Placebo
- Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more
- Conditions
- Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
- Interventions
- Letrozole 2.5mg, Placebo
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 53 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Breast Neoplasms
- Interventions
- PD-0332991, Letrozole, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 136
- States / cities
- Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo, Taselisib
- Drug · Other
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Femara, Placebo
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Neoplasm
- Interventions
- RAD001, Letrozole 2.5mg, Letrozole 2.5mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 10
- States / cities
- Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, exemestane, letrozole, sorafenib tosylate, placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- letrozole, Placebo
- Drug · Other
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Leiomyoma, Uterine Fibroids
- Interventions
- Letrozole, Placebo
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-dependent
- Interventions
- atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
- Drug · Procedure
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 17
- States / cities
- Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
- Conditions
- Advanced, Metastatic Breast Cancer
- Interventions
- Ribociclib, Letrozole, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more
- Conditions
- Breast Cancer
- Interventions
- lapatinib ditosylate, letrozole, placebo
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Breast Neoplasms, Neoplasm Metastasis
- Interventions
- LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 126
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 108 more
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Letrozole, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Stanford, California • Jacksonville, Florida • Miami, Florida + 6 more